- Auvelity net product sales were $119.6 million, up 84% year-over-year and 24% quarter-over-quarter.
- Cash and cash equivalents ended at $303 million, sufficient to fund operations into cash flow positivity.
- Gross to net discounts for Auvelity and Sunosi were in the mid-50% range; SYMBRAVO's gross to net was in the low 80% range.
- Net loss was $48 million or $0.97 per share, improved from $59.4 million loss in the previous quarter and $79.3 million loss in Q2 2024.
- R&D expenses were $49.5 million, slightly down from $49.9 million in Q2 2024 due to completion of certain trials, partially offset by higher personnel costs.
- Selling, general and administrative expenses increased to $130.3 million from $103.6 million, driven by commercialization activities and SYMBRAVO launch expenses.
- Sunosi net product revenues were $30 million, up 35% year-over-year and 19% quarter-over-quarter, including $1.1 million in royalty revenue.
- SYMBRAVO launched mid-June and generated $410,000 in net sales for the partial quarter.
- Total cost of revenue was $13.4 million, up from $8.1 million in Q2 2024.
- Total revenue for Q2 2025 was $150 million, representing 72% year-over-year growth and 24% sequential growth.
Related items and other data are not available for this feed item.
Dafinchi